IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
Autologous Peripheral Blood Stem Cell Transplantation With In Vivo Purging as an Alternate Stem Cell Transplantation Program for Pts w/AML in 1st & 2nd Complete Remission w/no HLA Matched Related Donor
This study has been completed.
Sponsor:
King Faisal Specialist Hospital & Research Center
Information provided by (Responsible Party):
King Faisal Specialist Hospital & Research Center
ClinicalTrials.gov Identifier:
NCT00531583
First received: September 17, 2007
Last updated: January 4, 2016
Last verified: January 2016
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Autologous peripheral Bld Stem Cell Transplantation with In Vivo Purging as an alternate stem cell transplantation program for pts w/AML in 1st & 2nd complete remission w/no HLA matched related donor
| Condition | Intervention |
|---|---|
| Leukemia, Monocytic, Acute | Drug: Autologous peripheral Bld Stem Cell Transplantation with In Vivo Purging as an alternate stem cell transplantation |
| Study Type: | Interventional |
| Study Design: | Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment |
| Official Title: | Autologous Peripheral Blood Stem Cell Transplantation With In Vivo Purging as an Alternate Stem Cell Transplantation Program for Pts w/AML in 1st & 2nd Complete Remission w/no HLA Matched Related Donor |
Further study details as provided by King Faisal Specialist Hospital & Research Center:
Primary Outcome Measures:
- Efficacy [ Time Frame: 2009-2015 ]
| Enrollment: | 350 |
| Study Start Date: | March 2001 |
| Study Completion Date: | June 2015 |
| Primary Completion Date: | June 2015 (Final data collection date for primary outcome measure) |
Intervention Details:
-
Drug: Autologous peripheral Bld Stem Cell Transplantation with In Vivo Purging as an alternate stem cell transplantation
Autologous PBSCT
Eligibility| Ages Eligible for Study: | 18 Years to 85 Years (Adult, Senior) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Patients with AML in 1st & 2nd complete remission w/no HLA matched related donor
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00531583
Please refer to this study by its ClinicalTrials.gov identifier: NCT00531583
Locations
| Saudi Arabia | |
| KFSH&RC | |
| Riyadh, Saudi Arabia, 1211 | |
Sponsors and Collaborators
King Faisal Specialist Hospital & Research Center
Investigators
| Principal Investigator: | Fahad AlMohareb | KFSH&RC |
More Information
| Responsible Party: | King Faisal Specialist Hospital & Research Center |
| ClinicalTrials.gov Identifier: | NCT00531583 History of Changes |
| Other Study ID Numbers: |
RAC#2001-004 |
| Study First Received: | September 17, 2007 |
| Last Updated: | January 4, 2016 |
Keywords provided by King Faisal Specialist Hospital & Research Center:
|
AML in 1st & 2nd complete remission w/no HLA matched related donor |
Additional relevant MeSH terms:
|
Leukemia, Monocytic, Acute Leukemia, Myeloid, Acute Leukemia, Myeloid |
Leukemia Neoplasms by Histologic Type Neoplasms |
ClinicalTrials.gov processed this record on September 21, 2017